论文部分内容阅读
目的分析阿替普酶(rt-PA)用于急性缺血性脑卒中患者静脉溶栓临床结局的影响因素。方法回顾性分析2013年1月-2016年8月医院接受rt-PA静脉溶栓的急性缺血性脑卒中患者61例的临床资料。结果 61例患者中,临床结局良好组23例,临床结局不良组38例。2组的年龄、基线血糖、基线NIHSS评分和早期症状改善率具有显著差异(P<0.05)。Logistic回归分析显示,年龄、基线NIHSS评分和早期症状改善是影响rt-PA静脉溶栓临床结局的独立预测因素(P<0.05)。结论年龄越大、基线NIHSS评分越高是临床结局不良的预测因素,相反,静脉溶栓后早期症状改善是临床结局良好的预测因素。
Objective To analyze the influence of alteplase (rt-PA) on the clinical outcomes of intravenous thrombolysis in patients with acute ischemic stroke. Methods The clinical data of 61 patients with acute ischemic stroke receiving intravenous thrombolysis rt-PA from January 2013 to August 2016 in our hospital were retrospectively analyzed. Results Of the 61 patients, 23 were clinically successful and 38 were clinically unsuccessful. There were significant differences in age, baseline blood glucose, baseline NIHSS score, and improvement in early symptoms between the 2 groups (P <0.05). Logistic regression analysis showed that age, baseline NIHSS score and early symptom improvement were independent predictors of clinical outcome of rt-PA intravenous thrombolysis (P <0.05). Conclusions The older, the higher the baseline NIHSS score is the predictor of poor clinical outcomes, whereas the improvement in early symptoms after intravenous thrombolysis is a good predictor of clinical outcomes.